207 related articles for article (PubMed ID: 31724905)
1. Effects of long-term antipsychotics treatment on body weight: A population-based cohort study.
Bazo-Alvarez JC; Morris TP; Carpenter JR; Hayes JF; Petersen I
J Psychopharmacol; 2020 Jan; 34(1):79-85. PubMed ID: 31724905
[TBL] [Abstract][Full Text] [Related]
2. Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database.
Osborn DP; Petersen I; Beckley N; Walters K; Nazareth I; Hayes J
J Psychopharmacol; 2018 Oct; 32(10):1098-1103. PubMed ID: 29938561
[TBL] [Abstract][Full Text] [Related]
3. Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study.
Chyou TY; Nishtala R; Nishtala PS
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):692-700. PubMed ID: 32301237
[TBL] [Abstract][Full Text] [Related]
4. Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
Dias Alves M; Micoulaud-Franchi JA; Simon N; Vion-Dury J
J Clin Psychopharmacol; 2018 Dec; 38(6):555-562. PubMed ID: 30247179
[TBL] [Abstract][Full Text] [Related]
5. Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.
Spertus J; Horvitz-Lennon M; Normand ST
Med Decis Making; 2019 Jul; 39(5):583-592. PubMed ID: 31375050
[TBL] [Abstract][Full Text] [Related]
6. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Bobes J; Rejas J; Garcia-Garcia M; Rico-Villademoros F; García-Portilla MP; Fernández I; Hernández G;
Schizophr Res; 2003 Jul; 62(1-2):77-88. PubMed ID: 12765747
[TBL] [Abstract][Full Text] [Related]
7. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
8. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
9. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
10. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.
Layton D; Harris S; Wilton LV; Shakir SA
J Psychopharmacol; 2005 Sep; 19(5):473-82. PubMed ID: 16166184
[TBL] [Abstract][Full Text] [Related]
11. No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment.
Schoretsanitis G; Drukker M; Van Os J; Schruers KRJ; Bak M
Acta Psychiatr Scand; 2018 Aug; 138(2):110-122. PubMed ID: 29602172
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.
Prabhakar M; Haynes WG; Coryell WH; Chrischilles EA; Miller del D; Arndt S; Ellingrod VL; Warren L; Fiedorowicz JG
Pharmacotherapy; 2011 Aug; 31(8):806-12. PubMed ID: 21923607
[TBL] [Abstract][Full Text] [Related]
13. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
14. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
15. Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.
Marras C; Herrmann N; Anderson GM; Fischer HD; Wang X; Rochon PA
Am J Geriatr Pharmacother; 2012 Dec; 10(6):381-9. PubMed ID: 23217531
[TBL] [Abstract][Full Text] [Related]
16. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
[TBL] [Abstract][Full Text] [Related]
17. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
[TBL] [Abstract][Full Text] [Related]
18. Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine.
Osborn D; Marston L; Nazareth I; King MB; Petersen I; Walters K
Schizophr Res; 2017 May; 183():116-123. PubMed ID: 27884434
[TBL] [Abstract][Full Text] [Related]
19. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
Perez-Iglesias R; Crespo-Facorro B; Martinez-Garcia O; Ramirez-Bonilla ML; Alvarez-Jimenez M; Pelayo-Teran JM; Garcia-Unzueta MT; Amado JA; Vazquez-Barquero JL
Schizophr Res; 2008 Feb; 99(1-3):13-22. PubMed ID: 18053689
[TBL] [Abstract][Full Text] [Related]
20. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
